Skip to main content

Table 2 preoperative chemotherapy response of patients who accepted two kinds of conversion chemotherapy regimen

From: Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study

Preoperative

chemotherapy

response

Apatinib plus SOX regimen, n (%)

SOX regimen, n (%)

P value

CR

0

0

0.497

PR

15 (71.4)

16 (55.2)

 

SD

4 (14.3)

9 (31.0)

 

PD

2 (9.5)

4 ((13.8)

 

ORR

15(71.4)

16(55.2)

0.382

DCR

19(90.5)

25(86.2)

0.986